Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer

• Published in: British journal of cancer Vol. 118; no. 10; pp. 1377 - 1381
• Main Authors: Lagheden, Camilla, Eklund, Carina, Lamin, Helena, Kleppe, Sara Nordqvist, Lei, Jiayao, Elfström, K Miriam, Sundström, Karin, Andrae, Bengt, Sparén, Pär, Dillner, Joakim
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.05.2018; Nature Publishing Group UK
• Subjects: Cervical cancer; Cervix; DNA, Viral - genetics; DNA, Viral - isolation & purification; Early Detection of Cancer; Female; Genotype; Genotyping; Health risk assessment; Human papillomavirus; Humans; Invasiveness; Linkage analysis; Medical screening; Medicin och hälsovetenskap; Oncogene Proteins, Viral - genetics; Papillomaviridae - classification; Papillomaviridae - genetics; Papillomaviridae - pathogenicity; Papillomavirus E7 Proteins - genetics; Papillomavirus Infections - classification; Papillomavirus Infections - genetics; Papillomavirus Infections - virology; Repressor Proteins - genetics; Sweden - epidemiology; Uterine Cervical Neoplasms - classification; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - virology; Sweden
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/s41416-018-0053-6

The Swedish National Cervical Screening Registry collects and evaluates comprehensive, nationwide health data to optimise organised cervical cancer prevention. Since all cervical cancer specimens are saved in biobanks, population-based data from the specimens should be available for analysis and linkage with other health information. We identified all cervical cancers diagnosed in Sweden during 2002-2011 (4254 confirmed cases) and requested the tissue blocks to retrieve human papillomavirus (HPV) genotype data using general primer PCR with Luminex genotyping and real-time PCR targeting the E6/E7 regions of HPV16/18. We obtained blocks from 2932/4254 (69%) of cases. Valid HPV genotyping data was retrieved for 2850 cases (97%). The most common type was HPV16 (60%), followed by HPV18 (19%), HPV45 (7%), HPV31 (3%), HPV33 (2%), HPV52 (2%), HPV39 (1%), HPV70 (1%), HPV56 (1%), HPV35 (1%), HPV58 (1%) and HPV59 (1%). Ninety-six percent of all HPV-positive cases had a single infection. Eighty-nine cases were HPV-positive only when testing for the HPV16/18-E6/E7 region. We present one of the largest series of HPV-genotyped cervical cancers to date. The systematic collection of cervical cancer HPV genotyping data by the screening registry will facilitate prevention and monitoring of HPV type-specific disease burden.